News & Events

Rewind Therapeutics Strengthens Scientific Advisory Board

Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor

Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team

ECTRIMS 2022, October 26-28, Amsterdam, The Netherlands

Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer

Rewind Therapeutics appoints Anja Harmeier, PhD, MBA, as Chief Executive Officer

Rewind Therapeutics appoints Kees Been as Non-Executive Director